Efficacy and Safety of Bevacizumab in Chinese Patients with Metastatic Colorectal Cancer

被引：3

作者：

Zhu, Li-Ming ^{[1
]}

Zhao, Ya-Zhen ^{[1
]}

Ju, Hai-Xing ^{[2
]}

Liu, Lu-Ying ^{[3
]}

Chen, Lei ^{[1
]}

Liu, Bi-Xia ^{[1
]}

Xu, Qi ^{[1
]}

Luo, Cong ^{[1
]}

Ying, Jie-Er ^{[1
]}

Yang, Yun-Shan ^{[1
]}

Zhong, Hai-Jun ^{[1
]}

机构：

[1] Zhejiang Canc Hosp, Dept Gastrointestinal Med Oncol, Hangzhou, Zhejiang, Peoples R China

[2] Zhejiang Canc Hosp, Dept Surg, Hangzhou, Zhejiang, Peoples R China

[3] Zhejiang Canc Hosp, Dept Radiotherapy, Hangzhou, Zhejiang, Peoples R China

来源：

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 2014年 / 15卷 / 16期

关键词：

Metastatic colorectal cancer; chemotherapy; bevacizumab; efficacy; tolerability; 1ST-LINE TREATMENT; OXALIPLATIN; FLUOROURACIL; CHEMOTHERAPY; LEUCOVORIN; FOLFIRI; COMBINATION; FOLFOX4; TRIAL; MULTICENTER;

D O I：

10.7314/APJCP.2014.15.16.6559

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: To evaluate the efficacy and safety of bevacizumab in the treatment of patients with metastatic colorectal cancer (mCRC). Methods: In a single-center, observational study of 91 Chinese patients with mCRC who received bevacizumab in combination with chemotherapy was conducted. Objective response rates (ORRs), progression-free survival (PFS), overall survival (OS) and adverse events were recorded, and the relationships between various clinical factors and PFS or OS were evaluated by Cox proportional hazards models. Results: Treatment with bevacizumab and chemotherapy was effective and tolerable. Univariate analysis showed that PFS and OS were significantly associated with the Eastern Cooperative Oncology Group performance status (ECOG-PS) score, duration of bevacizumab exposure, and whether chemotherapy was continued after discontinuation of bevacizumab treatment. A multivariate analysis showed that the duration of bevacizumab exposure and whether chemotherapy was continued after discontinuation of bevacizumab were independent prognostic factors for PFS and OS. Conclusion: In Chinese mCRC population, the shorter the duration of exposure to bevacizumab and chemotherapy, the worse the prognosis is.

引用

页码：6559 / 6564

页数：6

共 24 条

[1] Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial [J].

Adams, Richard A. ;

Meade, Angela M. ;

Seymour, Matthew T. ;

Wilson, Richard H. ;

Madi, Ayman ;

Fisher, David ;

Kenny, Sarah L. ;

Kay, Edward ;

Hodgkinson, Elizabeth ;

Pope, Malcolm ;

Rogers, Penny ;

Wasan, Harpreet ;

Falk, Stephen ;

Gollins, Simon ;

Hickish, Tamas ;

Bessell, Eric M. ;

Propper, David ;

Kennedy, M. John ;

Kaplan, Richard ;

Maughan, Timothy S. .

LANCET ONCOLOGY, 2011, 12 (07) :642-653

[2] Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study [J].

Bendell, Johanna C. ;

Beikaii-Saab, Tanios S. ;

Cohn, Allen L. ;

Hurwitz, Herbert I. ;

Kozloff, Mark ;

Tezcan, Haluk ;

Roach, Nancy ;

Mun, Yong ;

Fish, Susan ;

Flick, E. Dawn ;

Dalal, Darshan ;

Grothey, Axel .

ONCOLOGIST, 2012, 17 (12) :1486-1495

[3] Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].

Bennouna, Jaafar ;

Sastre, Javier ;

Arnold, Dirk ;

Osterlund, Pia ;

Greil, Richard ;

Van Cutsem, Eric ;

von Moos, Roger ;

Maria Vieitez, Jose ;

Bouche, Olivier ;

Borg, Christophe ;

Steffens, Claus-Christoph ;

Alonso-Orduna, Vicente ;

Schlichting, Christoph ;

Reyes-Rivera, Irmarie ;

Bendahmane, Belguendouz ;

Andre, Thierry ;

Kubicka, Stefan .

LANCET ONCOLOGY, 2013, 14 (01) :29-37

[4] Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center trial TRC-0301 [J].

Chen, Helen X. ;

Mooney, Margaret ;

Boron, Matthew ;

Vena, Don ;

Mosby, Kimberly ;

Grochow, Louise ;

Jaffe, Carl ;

Rubinstein, Lawrence ;

Zwiebel, James ;

Kaplan, Richard S. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (21) :3354-3360

[5] Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study [J].

Chibaudel, Benoist ;

Maindrault-Goebel, Frederique ;

Lledo, Gerard ;

Mineur, Laurent ;

Andre, Thierry ;

Bennamoun, Mostepha ;

Mabro, May ;

Artru, Pascal ;

Carola, Elisabeth ;

Flesch, Michel ;

Dupuis, Olivier ;

Colin, Philippe ;

Larsen, Annette K. ;

Afchain, Pauline ;

Tournigand, Christophe ;

Louvet, Christophe ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5727-5733

[6] Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale [J].

Colucci, G ;

Gebbia, V ;

Paoletti, G ;

Giuliani, F ;

Caruso, M ;

Gebbia, N ;

Carteni, G ;

Agostara, B ;

Pezzella, G ;

Manzione, L ;

Borsellino, N ;

Misino, A ;

Romito, S ;

Durini, E ;

Cordio, S ;

Di Seri, M ;

Lopez, M ;

Maiello, E .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4866-4875

[7] Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial [J].

Cunningham, David ;

Lang, Istvan ;

Marcuello, Eugenio ;

Lorusso, Vito ;

Ocvirk, Janja ;

Shin, Dong Bok ;

Jonker, Derek ;

Osborne, Stuart ;

Andre, Niko ;

Waterkamp, Daniel ;

Saunders, Mark P. .

LANCET ONCOLOGY, 2013, 14 (11) :1077-1085

[8] Treatment of Metastatic Colorectal Cancer With or Without Bevacizumab: Can the Neutrophil/Lymphocyte Ratio Predict the Efficiency of Bevacizumab? [J].

Dirican, Ahmet ;

Varol, Umut ;

Kucukzeybek, Yuksel ;

Alacacioglu, Ahmet ;

Erten, Cigdem ;

Somali, Isil ;

Can, Alper ;

Demir, Lutfiye ;

Bayoglu, Ibrahim Vedat ;

Akyol, Murat ;

Yildiz, Yasar ;

Koyuncu, Betul ;

Coban, Eyup ;

Tarhan, Mustafa Oktay .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (12) :4781-4786

[9] Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study [J].

Douillard, Jean-Yves ;

Siena, Salvatore ;

Cassidy, James ;

Tabernero, Josep ;

Burkes, Ronald ;

Barugel, Mario ;

Humblet, Yves ;

Bodoky, Gyoergy ;

Cunningham, David ;

Jassem, Jacek ;

Rivera, Fernando ;

Kocakova, Ilona ;

Ruff, Paul ;

Blasinska-Morawiec, Maria ;

Smakal, Martin ;

Canon, Jean-Luc ;

Rother, Mark ;

Oliner, Kelly S. ;

Wolf, Michael ;

Gansert, Jennifer .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4697-4705

[10] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

← 1 2 3 →